SOLID TUMOUR

This study tests capmatinib, a drug already approved for certain lung cancers, in adults with other rare cancers that have specific MET gene changes. About 30 participants will receive the drug to see if their tumors shrink or stop growing for at least 24 weeks. The goal is to fi…

This study tests a drug called entrectinib, already approved for certain lung and solid tumors, in people with rare cancers that have a specific genetic change called ROS1 fusion. About 30 adults, teens, and children with these rare cancers will receive the drug. Researchers will…

This study tests alectinib, a drug already approved for some lung cancers, in patients with rare cancers that have an ALK gene change. About 30 adults and children with ALK-positive cancers will receive alectinib to see if it shrinks tumors or stops them from growing. The goal is…

This study tests two drugs, trastuzumab and pertuzumab, already approved for breast cancer, in people with other rare cancers that have a specific genetic change called HER2 amplification or mutation. About 30 adults and children with various tumor types will receive the drug com…

This study tests two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific BRAF V600 gene change. About 30 people will take the drugs to see if their tumors shrink or stop growing. The goal is to find new uses fo…

This study tests whether drugs already approved for some cancers can help people with rare cancers or common cancers that have rare genetic changes. It includes adults, teenagers, and children whose cancer has a specific mutation and who have no other standard treatment options. …